ASTRO Virtual Meeting Center

Log-in / Create Account

Session Information

2010 Multidisciplinary Head and Neck Cancer Symposium

Click here to go to the previous page

General Session III: Discovery to Implementation of Biomarkers in Clinical Trials

Track : General Sessions

Program Code: 04

Date: Thursday, February 25, 2010

Time: 1:30 PM to 3:00 PM EST

Duration: 90 Minutes

Location: Akimel 3-4 Ballroom

MODERATOR:

Click the plus sign to see more detailed information about each speaker.

Thomas Carey, Ph.D., Professor, University of Michigan Cancer Center

I have been working on biomarkers in head and neck Cancer for ~30 years and I have published extensively on this topic. Recently we have completed several studies of biomarkers in in house phase II clinical trails that are prognostic of outcome and predictive of response to specific therapies. Recent papers on these topics include the following: Bauer JA, Trask DK, Kumar B, Los G, Castro J, Lee JS-J, Chen J, Wang S, Bradford CR, Carey TE, Reversal of cisplatin resistance with a BH3 mimetic, (-)-gossypol, in head and neck cancer cells: Role of wild-type p53 and Bcl-xL. Mol Cancer Ther 4:1096-1104, 2005. Kanazawa T, Iwashita T, Kommareddi P, Nair T, Misawa K, Misawa Y, Ueda Y, Tono T, Carey TE. Galanin and galanin receptor 1 suppress proliferation in squamous carcinoma cells: Activation of the extracellular signal regulated kinase pathway and induction of cyclin-dependent kinase inhibitors. Oncogene 26:5762-5771, 2007. Kumar B, Cordell KG, Lee JS, Prince ME, Tran HH, Wolf GT, Urba SG, Worden FP, Chepeha DB, Teknos TN, Eisbruch A, Tsien CI, Taylor JMG, DSilva NJ, Yang K, Kurnit DM, Bradford CR, Carey TE. Response to therapy and outcome in oropharyngeal cancer are predicted by biomarkers including HPV, EGFR, gender and smoking. Int J Radiat Oncol Biol Phys 69(2 Suppl):S109-111, 2007. (PMCID: PMC2084353)Kumar B, Cordell KG, DSilva N, Prince M, Adams M, Fisher SG, Wolf G, Carey TE, Bradford CR. Expression of p53 and Bcl-xL as predictive markers for larynx preservation in advanced laryngeal cancer. Arch Otolaryngol Head Neck Surg 134:363-369, 2008. Kumar B, Cordell KG, Lee JS, Worden FP, Prince ME, Tran HH, Wolf GT, Urba SG, Chepeha DB, Teknos TN, Eisbruch A, Tsien CI, Taylor JMG, DSilva NJ, Yang, K, Kurnit DM, Bauer JA, Bradford CR, Carey TE. EGFR, p16, HPV titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 26:3128-3137, 2008. Worden FP, Kumar B, Lee JS, Wolf GT, Cordell KG, Taylor JMG, Urba SG, Eisbruch A, Teknos TN, Chepeha DB, Prince ME, Tsien CI, DSilva NJ, Yang K, Kurnit DM, Mason HL, Miller TH, Wallace NE, Bradford CR, Carey TE. Chemoselection as a strategy for organ preservation in advanced oropharynx cancer:Response and survival positively associated with HPV16 copy number. J Clin Oncol 26:3138-3146, 2008. Misawa K, Ueda Y, Kanazawa T, Misawa Y, Jang I, Brenner JC, Ogawa T, Takebayashi S, Grenman RA, Herman JG, Mineta H, Carey TE. Epigenetic inactivation of GALR1 in head and neck cancer. Clin Cancer Res 14:7604-13, 2008.Maxwell JH, Kumar B, Feng FY, McHugh JB, Cordell KG, Eisbruch A,; Worden FP, Wolf GT, Prince ME,

SPEAKER(S):

Click the plus sign to see more detailed information about each speaker.

Antonio Jimeno, M.D., Ph.D., Assistant Professor, University of Colorado Denver

Thomas Carey, Ph.D., Professor, University of Michigan Cancer Center

Christine Chung, M.D., Assistant Professor, Vanderbilt University

Soren Bentzen, Ph.D., D.Sc., Professor, University of Wisconsin Medical School

Audio Synchronized to PowerPoint

(Code: 04)

Member:

Members Login